Journal article
Limosilactobacillus reuteri DSM‐17938 for preventing cough in adults with mild allergic asthma: A double‐blind randomized placebo‐controlled cross‐over study
Abstract
BACKGROUND: Cough is a common troublesome symptom in asthma which is neuronally mediated. Limosilactobacillus reuteri DSM-17938 (L. reuteri DSM-17938) is a probiotic shown to be effective in pre-clinical models at suppressing neuronal responses to capsaicin, a transient receptor potential vanilloid agonist (TRPV1).
OBJECTIVE: Investigate the effects of DSM-17938 versus matched placebo on capsaicin-evoked coughs in mild allergic asthmatics.
Authors
Satia I; Cusack R; Stevens C; Schlatman A; Wattie J; Mian F; Killian KJ; O’Byrne PM; Bienenstock J; Forsythe P
Journal
Clinical & Experimental Allergy, Vol. 51, No. 9, pp. 1133–1143
Publisher
Wiley
Publication Date
September 2021
DOI
10.1111/cea.13976
ISSN
0954-7894